Ramírez-Villafaña M, Muñoz-Rocha AD, Torres-Zaragoza Y, Mendoza-Vázquez G, Díaz-Rizo V, Hernández-Cuervo P, Flores-Chávez A, Félix-Hernández F, Álvarez-Pinto J, Guerrero-Aguilar LD, Rodríguez-Hernández TM, Ayala-Pérez D, Rodríguez-González M, Corona-Sánchez E, Martin-Márquez T, Vázquez MM, Cardona-Muñoz EG, Salazar-Páramo M, González-López L

Language: Spanish
References: 9
Page: 63-69
PDF size: 278.97 Kb.

ABSTRACT

Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory condition that is associated with potential complications of multi-organic leves with cardiovascular morbidity and mortality. RA treatment is aimed at relieving symptoms and alter the course of disease; however, the chronic use of corticosteroids, side effects metabolic character. Objective: This study aims to evaluate the association between the cumulative dose of corticosteroids and the percentage of body fat mass in patients with RA. Methods: Cross-sectional study. We evaluated 85 women diagnosed with RA. We identified demographic, clinical, biochemical and anthropometric. The cumulative dose volume by reviewing records. Assessment of fat free mass and body composition study by DXA. Results: Mean age was 53.7 ± 11.9 years, disease progression of 9.7 ± 8.0 years, BMI 27.9 ± 4.8 kg/m² establishing an overweight range to 33.8% of patients and 33% obese. Percentage of fat mass mean 45.14 ± 5.29 determined by DEXA. The 96.5% had treatment with corticosteroids at the time of assessment with an average of 3.7 ± 3.5 years of use and cumulative dose 6.8 ± 6.6 g. Positive correlation, but with a poor significance between% body fat and years of steroid use (R = 0.11, p = 28). Conclusions: There was no relationship between the cumulative dose of corticosteroids and increased percentage of body fat mass in patients with rheumatoid arthritis.

REFERENCES

1. Goronzy JJ, Weyand CM. Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res Ther. 2009; 11: 249.

2. Cardiel MH, Rojas-Serrano J. Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol. 2002; 20: 617-24.

3. Morales-Romero J, Cázares-Méndez JM, Gámez-Nava JI, Triano-Páez M, Villa-Manzano AI, López-Olivo MA et al. Patterns of health care in an our patient rheumatologic clinic. Reumatol Clin. 2005; 1: 87-94.

4. Domínguez MC, Lorenzo N, Barbera A, Darrasse-Jeze G, Hernández MV, Torres A, Hernández I et al. An altered peptide ligand corresponding to a novel epitope from heat-shock protein 60 induces regulatory T cells and suppresses pathogenic response in an animal model of adjuvant-induced arthritis. Autoimmunity. 2011; 44: 471-482.

5. Puente Torres L, Hurtado Torres GF, Abud Mendoza C, Bravo Ramírez A. Assessment of nutritional status in a mexican population of adult patients with rheumatoid arthritis. Nutr Hosp. 2009; 24: 233-238.

6. Salas-Salvadó J, Rubio MA, Barbany M, Moreno B, Grupo Colaborativo de la SEEDO. Consensus for the evaluation of overweight and obesity and the establishment of therapeutic intervention criteria. Med Clin (Barc). 2007; 128: 184-196.

7. Cardiel MH, Abello-Banfi M, Ruiz-Mercado R, Alarcon-Segovia D. How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI). Clin Exp Rheumatol. 1993; 11: 117-121.

8. Sidiropoulos PI, Karvounaris SA, Boumpas DT. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications. Arthritis Res Ther. 2008; 10: 207.

9. Dykman TR, Gluck OS, Murphy WA, Hahn TJ, Hahn BH. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum. 1985; 28: 361-368.